Nirmatrelvir-Ritonavir for Acute Covid-19 in Patients with Cardiovascular Disease and Post-Acute Sequelae of SARS-CoV-2-Infection (JACC: Advances June 2024)-Article: Nirmatrelvir-Ritonavir for Acute Covid-19 in Patients with Cardiovascular Disease and Post-Acute Sequelae of SARS-CoV-2-Infection

Article: Nirmatrelvir-Ritonavir for Acute Covid-19 in Patients with Cardiovascular Disease and Post-Acute Sequelae of SARS-CoV-2-Infection

Back to course

Pdf Summary

The study conducted by Patel et al. aimed to investigate the association between nirmatrelvir-ritonavir (NMV-r) treatment and the incidence of postacute sequelae of SARS-CoV-2 infection (PASC) in nonhospitalized, vaccinated patients with pre-existing cardiovascular disease (CVD). The retrospective cohort study utilized the TriNetX research network to analyze data from vaccinated patients with CVD who developed COVID-19 between December 2021 and December 2022. Two cohorts were created based on NMV-r administration within 5 days of diagnosis.<br /><br />The results showed that patients treated with NMV-r had a lower incidence of broadly and narrowly defined PASC symptoms between 30 to 90 days and 90 to 180 days post-infection compared to non-NMV-r treated patients. Additionally, NMV-r treated patients had reduced risk of cardiovascular, respiratory, gastrointestinal, nervous system, and mood disorder symptoms associated with PASC. The study also found lower health care utilization, including less frequent radiology and cardiovascular tests, and ambulatory or virtual visits in NMV-r treated patients.<br /><br />The study suggests that NMV-r treatment in nonhospitalized, vaccinated patients with pre-existing CVD and COVID-19 may reduce the burden of PASC and associated symptoms, potentially decreasing long-term complications of the virus. Further prospective studies are needed to confirm the effectiveness of antiviral therapy in reducing the incidence of PASC. The study highlights the importance of considering antiviral therapy in high-risk patient populations to mitigate the long-term effects of COVID-19.

Keywords

nirmatrelvir-ritonavir

NMV-r treatment

postacute sequelae of SARS-CoV-2 infection

PASC

nonhospitalized patients

vaccinated patients

pre-existing cardiovascular disease

retrospective cohort study

TriNetX research network

antiviral therapy